CME / ABIM MOC / CE

Acute Leukemias

Authors: Courtney D. DiNardo, MD, MSCE; Harry P. Erba, MD, PhD; Naval G. Daver, MD; Elias J. Jabbour, MD; Aaron C. Logan, MD, PhD; Jae H. Park, MD; Jessica Leonard, MD
CME / ABIM MOC / CE Released: 10/19/2022
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 10/19/2023, 11:59 PM EST

Target Audience and Goal Statement

This activity is intended for hematologist/oncologists, nurses, nurse practitioners (NPs), physician assistants (PAs), and pharmacists involved in the care of patients with hematologic disorders, including leukemias, lymphomas, multiple myeloma, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPNs), benign hematologic diseases, and other related conditions.

The goal of this activity is that learners will be better able to risk stratify and personalize treatment for patients with acute leukemias by integrating clinical trial data and evidence-based recommendations on novel therapies in the frontline and relapsed/refractory (R/R) settings.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Use of molecular analysis and risk stratification to guide therapy selection for patients with acute leukemias
- Recent clinical trial data on treatment strategies for acute leukemias in the frontline and R/R settings
Have greater competence related to
- Assessing measurable residual disease (MRD) in acute leukemias
- Selecting evidence-based treatment for patients with acute leukemias in the frontline and R/R settings
Demonstrate greater confidence in their ability to
- Personalize treatment for patients with acute leukemias in an interprofessional team-based environment

Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.

Faculty

Courtney D. DiNardo, MD, MSCE

Associate Professor
Department of Leukemia
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Disclosures

Courtney D. DiNardo, MD, MSCE, has the following relevant financial relationships:
Consultant or advisor for: AbbVie; Agios/Servier; Astellas; Celgene/Bristol Myers Squibb; Cleave; Foghorn; Genentech; Gen Mab; Novartis; Notable Labs; Takeda
Research funding from: AbbVie; Agios/Servier; Astex; Calithera; Celgene/Bristol Myers Squibb; Cleave; Foghorn; ImmuneOnc; Loxo

Harry P. Erba, MD, PhD

Professor of Medicine
Director, Leukemia Program
Duke University
Durham, North Carolina

Disclosures

Harry P. Erba, MD, PhD, has the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Astellas; Bristol Myers Squibb Company; Daiichi Sankyo; Genentech; Glycomimetics; Incyte; Jazz; Novartis; Servier
Served as a speaker or a member of a speakers bureau for: AbbVie; Bristol Myers Squibb Company; Incyte; Jazz; Novartis; Servier

Naval G. Daver, MD

Director
Leukemia Research Alliance Program
Associate Professor
Department of Leukemia
University of Texas MD Anderson Cancer Center
Houston, Texas

Disclosures

Naval G. Daver, MD, has the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Agios; Arog; Astellas; Bristol Myers Squibb Company; Celgene; Daiichi Sankyo; Genentech; Gilead; Immunogen; Jazz; Novartis; Pfizer; Servier; Shattuck Labs; Syndax; Trillium
Received grants for clinical research from: AbbVie; Amgen; Bristol Myers Squibb Company; Daiichi Sankyo; FATE Therapeutics; Genentech; Gilead; Glycomimetics; Hanmi; Immunogen; Novimmune; Pfizer; Servier; Trillium; Trovagene

Elias J. Jabbour, MD

Professor
Department of Leukemia
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Disclosures

Elias J. Jabbour, MD, has the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Amgen; Bristol Myers Squibb Company; Genentech; Novartis; Pfizer; Takeda
Received grants for clinical research from: AbbVie; Amgen; Pfizer; Takeda

Aaron C. Logan, MD, PhD

Associate Professor
Hematology, Bone Marrow Transplantation, and Cellular Therapy
University of California, San Francisco
San Francisco, California

Disclosures

Aaron C. Logan, MD, PhD, has the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Bristol Myers Squibb Company; Pfizer
Received grants for clinical research from: Amgen; Amphivena; Astellas; Autolus; Jazz; Kadmon; Kite; Pharmacyclics

Jae H. Park, MD

Associate Professor
Weill Cornell Medicine
Director, Adult ALL Program
Memorial Sloan Kettering Cancer Center
New York, New York

Disclosures

Jae H. Park, MD, has the following relevant financial relationships:
Served as an advisor or consultant for: Affyimmune; Allogene; Amgen; Artiva; Autolus; Bristol Myers Squibb Company; Curocel; Kite; Kura; Minerva; Novartis; Pepromene; Pfizer; Servier; Umoja
Received grants for clinical research from: Autolus; Fate; Genentech; Servier; Takeda

Jessica Leonard, MD

Assistant Professor of Medicine
Division of Hematology/Medical Oncology
Oregon Health and Science University
Portland, Oregon

Disclosures

Jessica Leonard, MD, has no relevant financial relationships.

Editor

Heather P. Friedman, MPH

Medical Education Director, Medscape, LLC

Disclosures

Heather P. Friedman, MPH, has no relevant financial relationships.

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 1.75 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.50 contact hours are in the area of pharmacology.

Contact This Provider

For Pharmacists

Medscape designates this continuing education activity for 1.75 contact hour(s) (0.175 CEUs) (Universal Activity Number: JA0007105-0000-22-356-H01-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC / CE

Acute Leukemias

Authors: Courtney D. DiNardo, MD, MSCE; Harry P. Erba, MD, PhD; Naval G. Daver, MD; Elias J. Jabbour, MD; Aaron C. Logan, MD, PhD; Jae H. Park, MD; Jessica Leonard, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 10/19/2022

Valid for credit through: 10/19/2023, 11:59 PM EST

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Intensive Frontline Therapy for AML

How are recent updates to the ELN genetic risk classifications affecting intensive frontline management of AML?
Harry P. Erba, MD, PhD

Lower-Intensity Frontline Therapy for AML

What’s the latest on doublet and triplet combinations for patients with AML who are ineligible for intensive chemotherapy?
Courtney D. DiNardo, MD, MSCE

Relapsed/Refractory AML

Which targeted therapies, immunotherapies, and emerging agents are showing the most promise in pretreated AML?
Naval G. Daver, MD

Philadelphia-Positive ALL

Could the high molecular response rates to the newest TKI regimens mean the end of transplant and chemotherapy in Ph-positive ALL?
Elias J. Jabbour, MD

Philadelphia-Negative ALL: Immunotherapy in the Frontline

How could moving novel immunotherapies to the frontline improve outcomes in Ph-negative ALL?
Aaron C. Logan, MD, PhD

Relapsed/Refractory ALL: Sequencing vs CAR T-Cell Therapy

What’s the future of relapsed/refractory ALL management: CAR T cells, immunotherapies, or both?
Jae H. Park, MD

Assessing Measurable Residual Disease in Acute Leukemias

How should we be using MRD to assess response and guide treatment decisions in AML and ALL?
Jessica Leonard, MD

Learning Feedback Questions

Please answer these questions to complement your learning experience.

Page 1 of 10

CME / ABIM MOC / CE Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Courtney D. DiNardo, MD, MSCE

Harry P. Erba, MD, PhD

Naval G. Daver, MD

Elias J. Jabbour, MD

Aaron C. Logan, MD, PhD

Jae H. Park, MD

Jessica Leonard, MD

Editor

Heather P. Friedman, MPH

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

CME / ABIM MOC / CE

Acute Leukemias

Target Audience and Goal Statement

Disclosures

Faculty

Courtney D. DiNardo, MD, MSCE

Harry P. Erba, MD, PhD

Naval G. Daver, MD

Elias J. Jabbour, MD

Aaron C. Logan, MD, PhD

Jae H. Park, MD

Jessica Leonard, MD

Editor

Heather P. Friedman, MPH

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

Acute Leukemias

Contents of This CME Activity

Intensive Frontline Therapy for AML

Lower-Intensity Frontline Therapy for AML

Relapsed/Refractory AML

Philadelphia-Positive ALL

Philadelphia-Negative ALL: Immunotherapy in the Frontline

Relapsed/Refractory ALL: Sequencing vs CAR T-Cell Therapy

Assessing Measurable Residual Disease in Acute Leukemias

Learning Feedback Questions